EGFR and prostate carcinoma: The major chemopreventive activities of EGCG include inhibition of the activity of many protein kinases, inhibiting the activity of the epidermal growth factor receptor (EGFR) in prostate cancer, inhibition of cell proliferation, induction of apoptosis, regulation of cell cycle arrest, interference of receptor binding, and suppression of angiogenesis.